Study of NK Combined With Chemotherapy for Advanced Solid Tumor
NCT04214730 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2023-03-28
Summary
Combinations Natural Killer Cell (NK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
Conditions
Interventions
- COMBINATION_PRODUCT
-
NK combined with Chemotherapy
Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
- DRUG
-
Patients will only receive Chemotherapy.
Sponsors & Collaborators
-
Yantai Yuhuangding Hospital
lead OTHER
Principal Investigators
-
Peiwen Lian, PhD · Yantai Yuhuangding Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 10 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-31
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- China
Study Locations
More Related Trials
-
Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT03432156 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer
NCT03198923 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
NCT06773091 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
NCT04137588 ·Status: UNKNOWN
-
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
NCT03007875 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
NCT02651441 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of NK510 to Treat NSCLC
NCT06097962 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06669611 ·Status: RECRUITING ·Phase: PHASE3
-
NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.
NCT03410368 ·Status: UNKNOWN ·Phase: PHASE2
-
Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT04212052 ·Status: COMPLETED ·Phase: PHASE2
-
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
NCT01667302 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
NCT07203352 ·Status: RECRUITING ·Phase: PHASE3
-
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
NCT02801487 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
NCT01631357 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)
NCT04990063 ·Status: UNKNOWN ·Phase: PHASE1
-
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
NCT07247201 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
NCT04331626 ·Status: UNKNOWN ·Phase: PHASE4
-
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
NCT06751901 ·Status: RECRUITING ·Phase: PHASE2
-
Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer
NCT01481259 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
NCT02843204 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients
NCT04061278 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
NCT02857920 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
NCT04054531 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma
NCT00817258 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
NCT02621333 ·Status: TERMINATED ·Phase: PHASE2